Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society

Pediatrics International

Volumn 56, Issue 1, 2014, Pages 1-5

  Sawai, Toshihiro ^a   Nangaku, Masaomi ^b   Ashida, Akira ^d   Fujimaru, Rika ^e   Hataya, Hiroshi ^f   Hidaka, Yoshihiko ^g   Kaname, Shinya ^h   Okada, Hirokazu ⁱ   Sato, Waichi ^j   Yasuda, Takashi ^k   Yoshida, Yoko ^l   Fujimura, Yoshihiro ^l   Hattori, Motoshi ^c   Kagami, Shoji ^m  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NARA MEDICAL UNIVERSITY   (Japan)

^m UNIVERSITY OF TOKUSHIMA   (Japan)

more..

Author keywords

ADAMTS13; alternative complement pathway; atypical hemolytic uremic syndrome; complement dysregulation; thrombotic microangiopathy

Indexed keywords

SHIGA TOXIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; END STAGE RENAL DISEASE; ESCHERICHIA COLI INFECTION; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; JAPAN; JAPANESE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; MEDICAL SOCIETY; NEPHROLOGY; STANDARDS; UROLOGIC EXAMINATION;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; DIAGNOSTIC TECHNIQUES, UROLOGICAL; GUIDELINES AS TOPIC; HUMANS; JAPAN; NEPHROLOGY; SOCIETIES, MEDICAL;

EID: 84894456703     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12274     Document Type: Article

References (15)

1. Gasser C, Gautier E, Steck A, Siebenmann R, Oechslin R,. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweizerische medizinische Wochenschrift. 1955; 85 (38-39): 905-909.
2. Konowalchuk J, Speirs J, Stavric S,. Vero response to a cytotoxin of Escherichia coli. Infection and Immunity. 1977.
3. Noris M, Remuzzi G,. Atypical hemolytic-uremic syndrome. The New England journal of medicine. 2009; 361 (17): 1676-1687.
4. Kavanagh D, Goodship T,. Genetics and complement in atypical HUS. Pediatric nephrology (Berlin, Germany). 2010; 25 (12): 2431-2442.
5. Kagami S, Okada H, Kaname S, Sato W, Nangaku M, Yasuda T, et al. Diagnostic driteria of atypical hemolytic uremic syndrome. J Jpn Pediatr Soc. 2013; http://www.jpeds.or.jp/uploads/files/saisin-130201.pdf (in Japanese).
6. Kagami S, Okada H, Kaname S, Sato W, Nangaku M, Yasuda T, et al. Diagnostic driteria of atypical hemolytic uremic syndrome. Jpn J Nephrol. 2013; 55 (2): 91-93 (in Japanese).
7. Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, et al. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clinical and experimental nephrology. 2011; 15 (5): 694-699.
8. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clinical journal of the American Society of Nephrology: CJASN. 2010; 5 (10): 1844-1859.
9. Legendre C, Licht C, Muus P, Greenbaum L, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England journal of medicine. 2013; 368 (23): 2169-2181.
10. Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Molecular immunology. 2013; 54 (2): 238-246.
11. Loirat C, Frémeaux-Bacchi V,. Atypical hemolytic uremic syndrome. Orphanet journal of rare diseases. 2011; 6: 60.
12. Stühlinger W, Kourilsky O, Kanfer A, Sraer J,. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet. 1974; 2 (7883): 788-789.
13. Nester C, Thomas C,. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012: 617-625.
14. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric nephrology (Berlin, Germany). 2009; 24 (4): 687-696.
15. Waters A, Licht C,. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric nephrology (Berlin, Germany). 2011; 26 (1): 41-57.